Novartis presented data at the European Society of Cardiology (ESC) Congress in Barcelona, Spain, which demonstrated that the addition of the angiotensin receptor blocker (ARB) Diovan (valsartan) to
PTC Therapeutics (PTC) has entered into an exclusive research collaboration and licensing agreement with Roche, for the development of orally bioavailable small molecules utilizing PTC’s technology – Gene
PTC Therapeutics (PTC) has reported that Celgene has exercised its option to collaborate on advancing drug discovery efforts on an oncology target addressed through the application of PTC’s
The Blanchette Rockefeller Neurosciences Institute (BRNI) has entered into an agreement with a group of neurological specialists (Brain Injury Group), to examine possible confluences of the Group’s work
Abbott has signed a definitive agreement to acquire Visiogen for $400m in cash, providing the company with a next-generation accommodating intraocular lens (IOL) technology to address presbyopia for
Generex Biotechnology has incorporated SIA ‘Generex Biotechnology BALTIC’ in the EU as a wholly-owned subsidiary of Generex. The purpose of the subsidiary is to harness and develop the
Ferguson has announced the launch of the Ferguson OTC (over-the-counter) Center of Excellence, a new initiative designed to address the rapid increase of promotion and use of OTC
BioDelivery Sciences announced the consolidation of the company’s laboratory and other operations in Newark, New Jersey to the company’s headquarters in Raleigh, North Carolina. BDSI will vacate its
Knopp Neurosciences (Knopp) has received Fast Track designation from the FDA for the development of KNS-760704 in amyotrophic lateral sclerosis (ALS). Knopp has completed the randomized, placebo-controlled portion
MethylGene has initiated its phase II program (Trial 103) evaluating MGCD265, the company’s multi-targeted (c-Met) kinase inhibitor, in combination with approved anticancer agents Tarceva and docetaxel. The trial
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.